Supernus Pharmaceuticals Inc (SUPN)
Current ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Total current assets | US$ in thousands | 493,113 | 734,151 | 601,590 | 630,417 | 472,644 |
| Total current liabilities | US$ in thousands | 290,196 | 687,958 | 315,379 | 245,108 | 160,587 |
| Current ratio | 1.70 | 1.07 | 1.91 | 2.57 | 2.94 |
December 31, 2023 calculation
Current ratio = Total current assets ÷ Total current liabilities
= $493,113K ÷ $290,196K
= 1.70
The current ratio of Supernus Pharmaceuticals Inc has shown fluctuating trends over the past five years. In 2023, the current ratio stands at 1.70, indicating the company's ability to cover its short-term liabilities with its current assets. However, compared to the previous year, there has been an improvement from 1.07 in 2022. Looking back, in 2021, the current ratio was relatively high at 1.91, signaling good liquidity and short-term solvency. In 2020 and 2019, the current ratio was even higher at 2.57 and 2.94, respectively, showcasing a stronger ability to meet short-term obligations with current assets.
The declining trend from 2019 to 2022, followed by a slight improvement in 2023, may indicate changes in the company's asset and liability management strategies. While the current ratio in 2023 shows some improvement, it is still lower than the levels observed in 2020 and 2019. Further analysis of the company's current assets and liabilities composition may provide insights into the factors influencing the current ratio dynamics and the overall liquidity position of Supernus Pharmaceuticals Inc.
Peer comparison
Dec 31, 2023